2 Healthcare Stocks for Beginner Investors With a 10-Year Time Horizon

Intuitive Surgical remains the dominant leader in robotic-assisted surgery with durable switching costs and annuity-like instruments, services and consumables driving strong results: Q3 2025 revenue $2.5 billion (+23% YoY) with $1.5 billion from instruments and accessories, $590 million systems, $396 million services, GAAP net income $709 million (+24%) and about $8.4 billion in cash and investments; the company benefits from an underpenetrated addressable market and ongoing product innovation. GE HealthCare, spun out in 2023, is a diversified medical-technology franchise embedding AI across imaging, monitoring and diagnostics (including foundation-model work and Project Health Companion) and reported Q3 revenue $5.1 billion (+6% YoY) with pharma diagnostics +20%, advanced visualization +7% and imaging +5%, net income $446 million and free cash flow ~$483 million, though margins are pressured by tariffs. For long-term portfolios, ISRG offers a high-margin, recurring-revenue growth profile tied to expanding procedure penetration, while GEHC provides broader, AI-enabled exposure across care pathways with a larger near-term operational headwind to monitor.

Analysis

Intuitive Surgical reported Q3 2025 revenue of $2.5 billion, up 23% year over year, with instruments and accessories contributing $1.5 billion, systems $590 million and services $396 million; GAAP net income rose 24% to $709 million and the company held about $8.4 billion in cash and investments. The revenue mix—annuity-like instruments, accessories and service contracts—combined with high switching costs from da Vinci system deployments underpins a durable economic moat and supports reinvestment in R&D.

GE HealthCare delivered Q3 revenue of $5.1 billion, up 6% year over year, with pharmaceutical diagnostics the fastest-growing segment (+20%), advanced visualization +7% and imaging +5%; the company generated $446 million in profit and roughly $483 million of free cash flow despite margin pressure from tariffs. The 2023 spin-off has accelerated product focus and GEHC is embedding AI across imaging and diagnostics (including foundation-model work and Project Health Companion) to improve workflow and differentiation.

For investors the contrast is clear: ISRG offers higher-margin, recurring-revenue exposure to an underpenetrated robotic-surgery market supported by product cycles and cash strength, while GEHC provides diversified, AI-enabled exposure across care pathways but carries near-term tariff-related margin risk and operational complexity that should be monitored closely.

Key Decisions for Investors

• Consider initiating or adding to a core long-term position in ISRG to capture recurring-instrument revenue and procedure penetration gains while sizing exposure to reflect its strong cash position and R&D-driven moat
• Consider a selective overweight or buy-on-weakness approach to GEHC to gain diversified, AI-enabled healthcare exposure, but monitor tariff-related margin pressure and trends in pharmaceutical diagnostics growth before increasing allocation
• Monitor catalysts and risks closely: track ISRG procedure penetration, instruments/services mix and regulatory approvals for new applications, and for GEHC watch tariff developments, free cash flow consistency and adoption metrics for AI-enabled products, and use position sizing or hedges to manage near-term operational headwinds